NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

AAV RPGR:新的醫藥品洞察與到2030年前的市場預測

AAV RPGR- Emerging Drug Insight and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 973300
出版日期 按訂單生產 內容資訊 英文 60 Pages
商品交期: 10個工作天內
價格
AAV RPGR:新的醫藥品洞察與到2030年前的市場預測 AAV RPGR- Emerging Drug Insight and Market Forecast - 2030
出版日期: 按訂單生產內容資訊: 英文 60 Pages
簡介

本報告提供7個主要市場(美國,歐洲5個國家(德國,法國,義大利,西班牙,英國),日本)的AAV RPGR市場的相關調查,刊載產品概要,2020年到2030年的預測銷售額資料,臨床實驗干預,臨床實驗條件,臨床實驗情形,涵括開始日和完成日的臨床試驗資訊,競爭情形,各國市場評估等資訊。

目錄

第1章 藥物概要

  • 產品詳細內容
  • 作用機制
  • 投藥和管理
  • 研究開發活動
    • 臨床開發
    • 安全性和有效性
  • 其他開發活動

第2章 市場評估

  • 主要7個國家 (7MM) 市場分析
  • 美國市場
  • 德國市場
  • 法國市場
  • 義大利市場
  • 西班牙市場
  • 英國市場
  • 日本市場

第3章 SWOT分析

第4章 分析師的見解

第5章 市場競爭

第6章 其他的新治療方法

第7章 附錄

第8章 購買報告的選擇

目錄
Product Code: DIDM0101

"AAV RPGR- Emerging Drug Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Retinitis pigmentosa in 7 Major Markets. A detailed picture of the AAV RPGR in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Drug Summary:

AAV-RPGR is an investigational gene therapy for the treatment of patients with XLRP caused by mutations in the eye specific form of the RPGR gene (RPGR ORF15). AAV-RPGR is designed to deliver functional copies of the RPGR gene to the subretinal space in order to improve and preserve visual function. MeiraGTx and development partner Janssen are currently conducting a phase I/II clinical trial of AAV-RPGR in patients with XLRP with mutations in RPGR ORF15. AAV-RPGR has been granted Fast Track and Orphan Drug designations by the U.S. Food and Drug Administration (FDA) and PRIME, ATMP and Orphan designations by the European Medicines Agency (EMA).

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around AAV RPGR.
  • The report contains forecasted sales for AAV RPGR till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) for Retinitis pigmentosa.
  • The report also features the SWOT analysis with analyst insights and key findings of AAV RPGR.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

AAV RPGR Analytical Perspective by DelveInsight

  • In-depth AAV RPGR Market Assessment

This report provides a detailed market assessment of AAV RPGR in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

  • AAV RPGR Clinical Assessment

The report provides the clinical trials information of AAV RPGR covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Retinitis pigmentosa is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence AAV RPGR dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Retinitis pigmentosa are giving market competition to AAV RPGR and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of AAV RPGR.
  • Our in-depth analysis of the forecasted sales data of AAV RPGR from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the AAV RPGR.

Key Questions:

  • Which company is developing AAV RPGR along with the phase of the clinical study?
  • What is the technology utilized in the development of AAV RPGR?
  • What is the product type, route of administration and mechanism of action of AAV RPGR?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the AAV RPGR development?
  • What are the key designations that have been granted to AAV RPGR?
  • What is the forecasted market scenario of AAV RPGR?
  • What is the history of AAV RPGR and what is its future?
  • What is the forecasted sales of AAV RPGR in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to AAV RPGR?
  • Which are the late-stage emerging therapies under development for the treatment of the Retinitis pigmentosa?

Table of Contents

1. Drug Overview

  • 1.1. Product Detail
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
  • 1.4. Research and development activity
    • 1.4.1. Clinical Development
    • 1.4.2. Safety and Efficacy
  • 1.5. Other Development Activities

2. Market Assesment

  • 2.1. 7MM Market Analysis
  • 2.2. The United States Market
  • 2.3. Germany Market
  • 2.4. France Market
  • 2.5. Italy Market
  • 2.6. Spain Market
  • 2.7. United Kingdom Market
  • 2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

List of Tables

  • Table 1 AAV RPGR, Description
  • Table 2 AAV RPGR, Clinical Trial Description
  • Table 3 AAV RPGR, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Table 4 Market Competitors
  • Table 5 Other Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of AAV RPGR
  • Figure 2 Patent Details, AAV RPGR
  • Figure 3 AAV RPGR, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Figure 4 AAV RPGR, US Market Size from 2020 to 2030 (in Millions USD)
  • Figure 5 AAV RPGR, EU5 Market Size from 2020 to 2030 (in Millions USD)
  • Figure 6 AAV RPGR, Japan Market Size from 2020 to 2030 (in Millions USD)